- Home
- GILD vs CRWD Comparison
GILD vs CRWD Comparison
Compare GILD & CRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | CRWD |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.6B | 174.3B |
| IPO Year | 2003 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GILD | CRWD |
|---|---|---|
| Price | $151.24 | $213.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 48 |
| Target Price | $148.39 | ★ $507.00 |
| AVG Volume (30 Days) | 5.3M | ★ 9.0M |
| Earning Date | 05-07-2026 | 06-02-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $24,689,000,000.00 | $4,812,005,000.00 |
| Revenue This Year | $4.68 | $24.85 |
| Revenue Next Year | $6.04 | $21.40 |
| P/E Ratio | ★ N/A | $7,128.17 |
| Revenue Growth | 9.98 | ★ 21.71 |
| 52 Week Low | $108.46 | $174.14 |
| 52 Week High | $157.29 | $786.00 |
Technical Indicators
Market Signals| Indicator | GILD | CRWD |
|---|---|---|
| Relative Strength Index (RSI) | 68.01 | 46.46 |
| Support Level | $142.93 | $178.38 |
| Resistance Level | $157.29 | $222.50 |
| Average True Range (ATR) | 3.51 | 12.47 |
| MACD | 0.32 | 7.04 |
| Stochastic Oscillator | 89.76 | 62.72 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-native cybersecurity company specializing in security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform, which provides enterprises with a unified view to detect and respond to security threats across their IT infrastructure. The Austin, Texas-based firm was founded in 2011 and went public in 2019.